JavidBasharat has defended his brother following the latter'sUltimate Fighting Championship departure.

FaridBasharat (16-0) completed his contract and wasn't offered a newdeal despite going 7-0 in the promotion, prompting debate aboutrecent roster decisions. Javid, whose UFC contract was not renewedin February, rejected CEO DanaWhite's suggestion that difficulties with matchmakers ordeclined fights could explain his brother's departure.
White was asked about Farid's departure at the UFC Edmonton postfight press conference. He suggested therewere reasons beyond Farid's results for the decision not to renewhis contract but did not identify a specific incident.

Farid responded on his Instagram Stories.

"A lot of ***** umptions made, but no facts were said," Farid wrote."I definitely wasn't turning down fights."

Javid echoed his brother's response, saying they had not discusseda contract renewal with the promotion.

"I can vouch that no fights were turned down nor were we hard todeal with as a matter of fact we have never had a conversation withregard to renewing the contract," Javid wrote. "We patiently waited3 months and we found out when everyone else found out!"

#contract #departure

Kansas City Chiefs quarterback Patrick Mahomes completed 23 of 30 passes for 272 yards, no touchdowns and one interception in Week 6 against the Los Angeles Chargers.
SOURCE: USA TODAY
Why it Matters: Mahomes didn't have to do much, as handing it off to Kenneth Walker III was extremely effective. That took a lot of pressure off of Mahomes, but fantasy managers don't feel any better about that. After a bye, patient fantasy managers who waited on Mahomes have to be a bit disappointed about the lack of touchdowns, although the yardage total was decent.
This article originally appeared on USA TODAY: Patrick Mahomes throws for 272 yards in Week 6

#mahomes #today #kansas #city

Improving Medicare Advantage ratings isn’t easy. Stars are based on 40-some criteria that encompass patient experience surveys and a range of care metrics.

#medicare #stars #patient

Matthew Lillard answered, "No. Not really," when asked whether he feels valued by Hollywood as an artist. The 56-year-old was speaking with Tommy DiDario on the Oct. 6 episode of I've Never Said This Before.
In an excerpt shared exclusively with PEOPLE, the Scream and Scooby-Doo actor said colleagues who have worked with him recognize what he brings to a production. He described trying to keep the atmosphere on set light while remaining dedicated to the work.
At conventions, he sees older and younger admirers waiting in long lines to meet him. He believes Hollywood underestimates that audience and said he takes pride in the connection he has built with fans.
Lillard emphasized that he is grateful to be approaching 40 years in the business. He said his frustrations were harder to live with when he was younger, when he was more impatient for a chance to move up.
Lillard described himself as quirky, gangly and energetic, capable of broad comedy and serious dramatic work. He said casting decision-makers are more comfortable with performers who fit a recognizable movie-star image, while his combination of qualities has made him harder to place.

#lillard

"Rocky" franchise star Dolph Lundgren was considering ending his life after a years-long battle with kidney cancer. Then a doctor "saved" his life by discovering a misdiagnosis had led to ineffective treatment.
The Swedish action star, 68, revealed in 2023 that he had been diagnosed with cancer eight years prior and that he'd been given a few years left to live after finding it had metastasized to other parts of his body. However, a review by another doctor's team led to the revelation that his cells showed a mutation commonly found in lung cancer patients.
Now, with his memoir, "Fights Worth Fighting: Finding Strength in Struggle," recently published and a documentary, "Dolph: Unbreakable," due for digital release, he is opening up about the highs and lows he's experienced since his 2015 diagnosis.
In a Us Weekly interview published Oct. 6, "The Expendables" actor explained that obtaining a second opinion "saved my life," adding that "I wouldn't have been sitting here right now" if his oncologist, Dr. Alexandra Drakaki, had not caught his misdiagnosis.
When he switched to a new medication, he felt "relief that it started working quite quickly."

#star

Kim Kardashian and Kanye West's kids have a squad of nannies helping them around the clock. During a recent interview, the 45-year-old mom revealed that she has help at home. While she reportedly hired five nannies, one is always on duty. For those unversed, the socialite has four kids: North, Saint, Chicago, and Psalm. She has primary custody of her children after her divorce from West.
Kim Kardashian has been raising her four kids with the help of five nannies. Recently, the reality TV star opened up about her personal life and daily routine in an interview with The Times. She talked about her children and how she's raising them. Kardashian admitted that she has a surprising amount of help.
She said that she has "one nanny on duty" and four nannies on rotation. With a whole help squad, Kardashian has been taking care of her four kids. Despite the nanny squad, she makes sure to be present in the children's lives as much as possible. Therefore, she is on school duty as the mom drops off and picks up the kids from school every day. She also has dinner with them daily and reads bedtime stories to them.
"I'm extremely patient and loving. I still have a kid sleep in my bed when they want. I read books with the kids every night," Kardashian said. Meanwhile, Saint, 10, Chicago, 8, and Psalm, 7, have not reportedly shown much interest in the entertainment world. But the socialite addressed how her eldest daughter, North, 13, has already been making her way into the music and fashion industries.
"Each kid does what they're comfortable with. So, my little ones come around when I'm filming, but they don't really do storylines. North loves it a little bit more than the rest," Kardashian added.

#kids #north #squad #Chicago

Kim Kardashian has opened up about raising her four children, North, Saint, Chicago, and Psalm, as a single mother. During a new interview with The Sunday Times Style, the reality star admitted that she has five nannies, with one on duty and four on rotation, to help look after her kids due to her busy work schedule.
The SKIMS founder explained that she is always available to drop her children to school every day, pick them up, and eat dinner with them. "I think I am an intermediate-strict parent," she shared. "I'm extremely patient and loving. I still have a kid sleep in my bed when they want. I read books with the kids every night."
Kim also shared that she believes it's important to discuss privilege with her children. "It's something I talk to my kids about constantly, about hard work, never taking things for granted, always having gratitude," she said. "I lead by example. I'm really open with them about my work, all of the hard work that I put into my law studies, and they're proud. I think that you can have a big life and still have that spirit in you. But it is more challenging."
Kim Kardashian opened up about raising her kids (@ Getty Images for This Is About H)
The beauty mogul also discussed how she co-parents with her ex-husband, Kanye West, when it comes to her daughter North's budding music career. The former couple were married from 2014 to 2022 and share four kids.

#four #think

Clark Howard calls Medicare Advantage plans "disadvantage plans," warning the new SCAN Costco HMO prioritizes cost savings over patient care through prior authorization denials.
In a serious illness year, a $0-premium Advantage plan can cost $6,807 more than Original Medicare plus Medigap Plan G, which caps costs at $283 annually.
Choosing Advantage at 65 may permanently lock you out of Medigap coverage if you get sick later, since most states allow insurers to deny or upcharge applicants.
Read More: Learn 7 ways to generate income with a $1,000,000+ portfolio (sponsor)
"Costco. Do you know what you're doing here? You know who you're messing around with?" Consumer advocate Clark Howard, usually one of the warehouse club's biggest fans, said that on his show on October 5.

#clark #plan #plans

President Donald Trump used an anti-trans slur Monday to attack the Democratic nominee for the Senate in South Carolina as he urged voters to back Republican Sen. Darline Graham.
In a Truth Social post, Trump referred to Democratic candidate Annie Andrews three times as “trannie.” He said Andrews, who is not transgender, is “not for South Carolina.”
“And South Carolina must show, in the upcoming Election, that it is not for her,” Trump added.
Andrews responded by largely ignoring the insult, saying in a statement first shared with NBC News that she will “work with anyone to put South Carolina first.”
“As a mom and a pediatrician, I’m in this race to fight for my patients, my three kids, and South Carolina,” Andrews said, adding that “lowering costs and making life better for families across our state is going to take all of us working together.”

#Trump

Kim Kardashian is pulling back the curtain on what it takes to raise four children while juggling her sprawling business empire and life in the spotlight, revealing that she employs five nannies to help keep her busy household running.
The 45-year-old reality TV star and entrepreneur opened up about her parenting routine during a recent interview with the Sunday Times, admitting that she has one nanny working at a time, while four others rotate in and out.
Kardashian shares daughters North, 13, and Chicago, 8, and sons Saint, 10, and Psalm, 7, with her ex-husband, Kanye West.
Despite having plenty of help on hand, the Skims founder insisted that she remains heavily involved in her children's everyday lives, from getting them to and from school to sitting down for dinner together.
"I am an intermediate-strict parent," Kardashian explained. "I'm extremely patient and loving. I still have a kid sleep in my bed when they want. I read books with the kids every night."

#four #Chicago #saint

Kate Middleton showed that green is one of her go-to colors for fall. While visiting the Royal Marsden NHS Foundation Trust in London, England, on September 11, 2026, the Princess of Wales arrived in a green apple midi dress by the British brand Suzannah London. The silk dress, known as the Flippy Wiggle Dress, featured black ****** ons running down the front with a tonal belt and short, capped sleeves. The dress was a re-wear for the royal; she first stepped out in the frock on May 18, 2023, while visiting the Anna Freud Centre in London. She likes that particular dress style so much that she also stepped out in a white version of the Flippy Wiggle dress with black detailing in July 2026. The white dress was Middleton's summer choice, while the green apple version is better suited to fall.
The hospital visit was a deeply personal one for the princess; Middleton received cancer treatment at the Royal Marsden Hospital in 2024, and so her visit during fall 2026 was an opportunity to connect with current patients and hospital staff. While it was obviously a very meaningful visit, it was also fitting that she chose to wear a green dress. In fashion, green symbolizes hope and new life, so her dress was a gesture of goodwill toward those in recovery.
Read more: Pamela Anderson & Kate Middleton Love The 'No-Manicure Manicure' Right Now
Wpa Pool/Getty
Kate Middleton has become an undisputed muse of fall fashion, and her enviable wardrobe provides endlessfall outfit inspo, featuring green as her signature color for the season. She wore the green apple Suzannah London dress on September 11, 2026, as proof. A few days earlier, on September 8, 2026, the princess wore a green Emilia Wickstead dress when she and Prince William dropped off Prince George for his first day at the elite boarding school, Eton College. It seems she's all about green for these meaningful events.

#green #september #hospital

LifeMD, Inc. (NASDAQ:LFMD) announced an exclusive healthcare collaboration on September 15 that initially makes virtual-health membership benefits available to approximately 29 million eligible AT&T wireless and fiber customers across 11 states. Customers must be 18 or older, and some services have additional eligibility and state restrictions. A nationwide expansion planned for January 2027 would extend eligibility beyond 100 million customers.
The $19 monthly membership fee is waived, but customers must enroll. Visits, prescriptions, and other services remain separately payable. For LifeMD, Inc. (NASDAQ:LFMD), the opportunity is converting access to a large audience into recurring demand for paid care.
The partnership gives LifeMD, Inc. (NASDAQ:LFMD) a distribution channel through the website, mobile app and customer-benefits program of AT&T Inc. (NYSE:T). Reaching customers through an established relationship could reduce reliance on advertising and lower acquisition costs per paying patient.
Removing the membership charge also reduces the financial commitment required to try the service. Announced visit prices start at $29 for message-based care, $49 for urgent and primary care video visits, and $79 for specialty care. Customers may use insurance, Medicare, or discounted cash-pay rates for visits and prescriptions.
LifeMD, Inc. (NASDAQ:LFMD) could benefit from repeat consultations and prescription fulfillment when clinically appropriate. Primary care, chronic-condition management and other services create opportunities for continuing patient relationships. If satisfied patients return, the revenue earned over those relationships could exceed the cost of acquiring and serving them.

#Services

Definium Therapeutics, Inc. (NASDAQ:DFTX) has now delivered a third consecutive positive Phase 3 readout for its LSD-based medication, the second in generalized anxiety disorder. The result puts the company on a viable route toward a potential FDA approval of an LSD-based treatment for generalized anxiety disorder, and considering how closely psychedelic stocks have historically traded on each other's data, the reading carries far more weight than Definium's own ticker.
On September 14, Definium Therapeutics, Inc. (NASDAQ:DFTX) announced that its drug DT120, an orally disintegrating tablet formulation of LSD, was successful in Panorama, the company's second late-stage anxiety trial. Over 12 weeks, patients who received a 100-microgram dose experienced a 9.8-point decline on the Hamilton Anxiety Rating Scale, a typical clinical measure, compared to a 4.7-point drop with placebo.
The resulting 5.1-point placebo-adjusted improvement is similar to what the company's first pivotal anxiety trial, Voyage, showed back in August: an 11.6-point improvement versus 6.2 for placebo, a 5.4-point separation that Jefferies called one of the strongest placebo-adjusted efficacy results ever seen in generalized anxiety disorder, and that Stifel simply described as "a clean win."
Psychedelic equities have a history of trading as a group rather than as individual names, and this tendency applies both ways. In February 2026, when Compass Pathways, the sector's other clinical leader developing a psilocybin-based drug for treatment-resistant depression, reported positive late-stage data, shares of Definium Therapeutics, Inc. (NASDAQ:DFTX), Atai Beckley, GH Research, and Helus Pharma all rose, some by double digits.
That correlation is significant here because Definium's win is an independent validation of the broader therapeutic argument on which Compass and others are betting: a single dose of a classic psychedelic, administered in a controlled clinical setting, can produce lasting improvements in serious mental health conditions via pathways different from existing SSRIs and other standard-of-care drugs.

#definium #placebo

ResMed Inc. (NYSE:RMD) is well positioned to benefit from the long-term growth of the global obstructive sleep apnea (OSA) treatment market. Likewise, the company remains well positioned to benefit from growing awareness and penetration in the global market, backed by a robust product portfolio.
The company's OSA portfolio includes CPAP and APAP machines, led by the AirSense platform. The AirSense 10 series is one of the most widely used CPAP and APAP machine series. Beyond sleep therapy machines, it also offers nasal, nasal-pillow, and full-face masks, along with a wide range of accessories and related products.
The broad product portfolio offers multiple avenues for generating recurring revenue beyond the initial sale of a sleep therapy device.
Monkey Business Images/Shutterstock.com
In the fourth quarter of fiscal 2026, ResMed's revenue increased 9% year over year to $1.5 billion, supported by strong demand for sleep devices, masks, and accessories. Americas device revenue increased 6%, while total Americas Sleep and Breathing Health revenue rose 8%. Americas masks and other revenue increased 10%. The stronger performance is particularly important as it highlights the ability to monetize the installed patient base beyond the initial device purchase.

#sleep #increased

Xenon Pharmaceuticals (XENE) shares crashed on Friday after the biopharmaceutical firm said it has paused new patient enrollment in its clinical trials evaluating azetukalner. As investors responded to the setback involving XENE's lead drug candidate for major depressive disorder, its relative strength index (RSI) slipped into the early teens, indicating extremely oversold conditions.
Following today's decline, Xenon Pharmaceuticals stock is trading nearly 40% below its year-to-date high.
Bank of America Just Declared a 'Generational Entry Point' in U.S. Bonds. Why Investors Should Be Backing Up the Truck on Treasuries Here.
Mark Cuban Says He Was Dizzy for Months, So He Built a VR Fix That Does at Home 'Much Of What A 180k Machine' Does
JPMorgan Gives Up Forecasting Iran War Endgame as Trump Tells Reporters 'Anything Could Happen With Me'

#xene #following #America

On September 16, IDEXX Laboratories (NASDAQ:IDXX) announced it had bought CoVetAI, a fast-growing veterinary software company whose tool listens during appointments and organizes what gets said and done. It sounds like a productivity gadget. But IDEXX is pitching it as a way to put the right patient details in front of a vet at the moment they decide what to test. The price was not disclosed, so the strategy is the story.
Start with the customer base IDEXX already has. More than 10,000 clinics worldwide run on its cloud practice software, and CoVet will plug into that system, including a link to IDEXX VetConnect PLUS. That hands a new product a ready audience. CoVet also works with practice systems IDEXX does not make, and IDEXX plans to keep supporting rival scribes, so the tool can reach clinics and regions the company does not serve today.
Then there is the engine this could feed. On August 4, IDEXX reported second-quarter revenue growth of 10%, and its recurring diagnostics business grew 11%, powered by higher volumes. That says vets are already running more tests, which is the behavior a smarter workflow tool is meant to encourage. The company also placed more than 1,600 inVue Dx ****** yzers in the quarter, lifting the installed base past 9,000, and it counts that instrument among its AI-driven products. Software and hardware are pointing in the same direction.
The biggest problem is what we can't see. Without deal terms, there is no way to judge what IDEXX paid or how much CoVet matters to earnings. And the company describes the payoff in future tense, saying these capabilities can raise diagnostic use over time. That is a hope, not a result yet. CoVet's openness to other systems cuts both ways too. It widens reach, but it also means a clinic can use CoVet without going deeper into IDEXX's ecosystem.
The second quarter also needs a careful read. Earnings per share rose 18%, but that included tax benefits from stock-based pay and a currency boost, and growth on a comparable basis was 15%. Some of the gain, in other words, did not come from selling more to vets. IDEXX also says it is spending more on commercial and innovation priorities, so its higher full-year earnings outlook comes with added costs attached.

#company #software #earnings #already

Interested in HCA Healthcare, Inc.? Here are five stocks we like better.
Exchange-related pressure is weighing on HCA's 2026 outlook: The expiration of enhanced tax credits is pushing some patients into uninsured status, with estimated full-year impact of $1 billion to $1.2 billion and slower elective-care utilization.
State supplemental payments and underlying demand provide offsets: HCA expects a $300 million to $500 million net benefit from state programs, while insured business excluding exchange plans grew 3.2% and adjusted admissions increased 2.7% in the second quarter.
HCA is pursuing long-term growth through capacity and efficiency investments: The company is expanding outpatient facilities, improving patient throughput and cost management, and maintaining a target of 4% to 6% long-term revenue growth with stable margins.
Healthcare Added 35,200 Jobs—3 Stocks Positioned to Benefit

#healthcare #Growth

On September 15, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) completed its acquisition of privately held Actio Biosciences for $820 million upfront, adding a clinical-stage epilepsy drug called ABS-1230 to its rare disease pipeline. The deal lands weeks after Jazz posted its highest quarterly revenue ever on August 3, and raised its full-year guidance, so a fresh acquisition now sits on top of a business that was already accelerating. The question for investors is whether that combination adds up to durable growth or just a bigger bill.
ABS-1230 targets KCNT1-related epilepsy, a rare and hard-to-treat form of the disease. In an early clinical proof-of-concept trial, children who received the drug experienced meaningful seizure reductions, and preclinical testing showed it inhibited KCNT1 across every pathogenic mutation researchers evaluated, hinting it could work across the whole patient population rather than a narrow subset. The FDA has already granted ABS-1230 Orphan Drug, Rare Pediatric Disease and Fast Track designations, and accepted it into the agency's Rare Disease Evidence Principles process, a set of regulatory advantages that can speed a drug toward approval.
The acquisition also arrives while Jazz's existing business is firing on multiple cylinders. Second-quarter revenue climbed 16% year over year to $1.2 billion, the company's highest quarterly total on record, and management raised full-year 2026 revenue guidance to a range of $4.6 billion to $4.75 billion. Growth was not confined to one product. Xywav sales rose 13% to $471 million on 525 net new patients, Epidiolex grew 16% to $292 million, and Zepzelca jumped 42% to $106 million. Zanidatamab, sold as Ziihera in biliary tract cancer, also received Breakthrough Therapy designation from the FDA for a form of colorectal cancer, adding another avenue for the oncology franchise Jazz has been building beyond its epilepsy and sleep businesses.
None of that came free. The $820 million upfront payment for Actio lands on top of $4.4 billion in long-term debt that Jazz already carried as of June 30, even after the company used part of its cash to repay $1.0 billion of exchangeable notes that matured this year. Cash, equivalents and investments stood at $2.2 billion at that point, meaning the Actio payment alone accounts for a meaningful share of the company's liquid resources.
Jazz's recent history also shows how acquisitions can distort the bottom line before they pay off. A $905.4 million in-process research and development charge tied to the 2025 Chimerix acquisition pushed second-quarter 2025 GAAP earnings to a loss of $11.74 per share, and a smaller $77 million IPR&D charge from the AbCellera and Werewolf deals still dented second-quarter 2026 results. ABS-1230 itself remains early, with only proof-of-concept data in hand and no late-stage trial results yet. The portfolio is not without setbacks, either. Jazz is moving to voluntarily drop the second-line indication for Zepzelca in meta

On September 8, 2026, CNBC reported that Novartis AG (NYSE:NVS) shares fell about 10% after the company said its experimental drug del-desiran failed to meet its primary goal in a late-stage trial for myotonic dystrophy type 1.
It marked the company's third clinical setback in a week following the earlier failure of cardiovascular drug pelacarsen and a separate pause of eight trials of cell therapy rap-cel after three patient deaths. The decline erased roughly 24 billion Swiss francs, or about $29.6 billion, in market value and put Novartis on pace for one of its worst trading days in company history.
Remibrutinib provides a major remaining pipeline catalyst since Novartis AG (NYSE:NVS) reported successful late-stage results for remibrutinib in multiple sclerosis. It gives investors a credible growth driver after the failures of pelacarsen and del-desiran. The business expects more remibrutinib data later this year, making the drug an important test of whether its remaining pipeline can help long-term growth.
Novartis still expects 5% to 6% annual sales growth through 2030. Management reaffirmed its full-year financial guidance and maintained its target for 5% to 6% compound annual sales growth from 2025 through 2030. That guidance shows the company still expects its overall portfolio and remaining pipeline ******* ets to offset pressure from aging drugs.
The company retains a diversified commercial portfolio. The del-desiran failure removes a potentially important future revenue contributor, but Novartis still makes substantial revenue from its existing medicines. It also retains other pipeline ******* ets. That diversification gives the firm financial capacity to absorb individual clinical failures while it rebuilds investor confidence in its growth pipeline.

#company #remibrutinib

On September 8, 2026, CNBC reported that Novartis' failed pelacarsen trial has raised the stakes for rival experimental cholesterol drugs from Amgen Inc. (NASDAQ:AMGN) and Eli Lilly and Company (NYSE:LLY), both of which are racing to prove that lowering lipoprotein(a), or Lp(a). It can meaningfully reduce heart attacks and strokes.
Analysts said Amgen's olpasiran faces the clearest negative read-through given its similar trial design. Lilly's lepodisiran is being tested in a broader patient population that could limit how directly Novartis' failure applies. It is also described as less material to Lilly's overall valuation than pelacarsen was for Novartis.
Copyright: stocking / 123RF Stock Photo
Amgen Inc. (NASDAQ:AMGN) and Eli Lilly and Company (NYSE:LLY) could still succeed where Novartis failed. Pelacarsen's failure does not establish that lowering Lp(a) cannot reduce cardiovascular events. **** ysts noted that Novartis' trial faced a high statistical hurdle and that Amgen's olpasiran and Lilly's lepodisiran have produced stronger Lp(a) reductions in earlier studies. Both companies also continue testing their drugs in specific patient populations with high Lp(a). It leaves room for their trials to produce different outcomes from Novartis' study.
Lilly's lepodisiran faces a less direct read-through than Amgen's olpasiran. **** ysts view Amgen's olpasiran as the closest comparison to pelacarsen because the programs use similar trial designs. Lilly's lepodisiran is being tested in an overall patient population. It could make Novartis' failure less directly applicable. **** ysts also view lepodisiran as less material to Lilly's overall valuation than pelacarsen was to Novartis. It reduces the potential financial impact of an unsuccessful outcome.

#lepodisiran #less

On September 7, 2026, Reuters reported that Novo Nordisk A/S (NYSE:NVO) halted two additional trials of its experimental cardiovascular drug ziltivekimab, further denting the Danish drugmaker's efforts to diversify beyond its blockbuster obesity and diabetes franchise.
The move follows a July disclosure that ziltivekimab failed to reduce major adverse cardiovascular events in a late-stage trial. An independent data monitoring committee found a "low likelihood" that the two additional heart-failure studies would produce a different result from that earlier failure, prompting Novo to end them ahead of schedule.
Novo Nordisk A/S (NYSE:NVO) still has one opportunity to create value from its cardiovascular program. The company will continue testing ziltivekimab in patients recovering from a heart attack, with results expected in the first half of 2027. A successful outcome could give Novo another growth opportunity outside its obesity and diabetes franchise.
Novo's core obesity and diabetes business remains the much larger driver of its financial performance. The oral Wegovy pill has already generated more than 2 million prescriptions shortly after its January 2026 launch. It gives Novo an important growth opportunity as the company competes with Eli Lilly in the oral GLP-1 market.
The company can also preserve capital by ending trials that show limited prospects for success. An independent data monitoring committee found a low likelihood that the two heart-failure studies would produce different results from the earlier failed trial. Novo can redirect the resources it would have spent on those studies toward higher-potential programs.

#obesity #diabetes

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) reported on September 14 that fiscal first-quarter 2027 revenue increased 60% to $31.0 million. Gross margin reached 56.5%, up from 45.7%, for the quarter ended July 31, 2026.
Management raised fiscal 2027 revenue guidance to $141 million from $137 million, implying 48% annual growth. The outlook strengthens the commercial story, but the expanding organization still consumes substantially more than the business generates in gross profit.
Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) attributed revenue growth to wearable cardioverter defibrillator market expansion, competitive share gains, new sales territories, a higher proportion of in-network patients and improvements in revenue cycle management.
These drivers suggest several ways to expand: reach more patients, improve reimbursement outcomes, and collect revenue more effectively. Their investment value depends on sustaining growth without requiring a matching increase in support costs.
Gross profit nearly doubled to $17.5 million from $8.9 million. Management attributed the margin improvement to higher volume, the in-network patient mix, and cost initiatives. The company is retaining more of each revenue dollar to fund selling expenses and product development.

#million #kestra #kmts

Ascendis Pharma A/S (NASDAQ:ASND) announced on September 14 that it will regain exclusive rights to develop, manufacture, and commercialize TransCon products in metabolic and cardiovascular diseases following the termination of its collaboration with Novo Nordisk A/S (NYSE:NVO).
The rights include once-monthly TransCon Semaglutide, an investigational long-acting prodrug of semaglutide intended for obesity and type 2 diabetes. Neither party will have continuing financial obligations to the other. Once termination becomes effective and the rights revert, management plans to initiate multiple programs across rare and large indications.
The investment question is whether greater control over future products can justify the resources needed to develop them.
Ascendis Pharma A/S (NASDAQ:ASND) would regain flexibility over which indications to pursue, how quickly to advance candidates, and whether to seek another partner. Successful independent development could retain more of a product's commercial economics, while a new collaboration could provide another way to share costs and risk.
Monthly dosing offers a clear development objective. If clinical studies demonstrate effective treatment with acceptable tolerability, fewer injections could make long-term therapy more convenient. That potential benefit would matter most if it helps patients stay on treatment without sacrificing outcomes.

#ascendis #pharma #asnd #regain

Pharming Group N.V. (NASDAQ:PHAR) announced on September 11 that the U.S. Food and Drug Administration approved Joenja for children aged 4–11 with activated PI3K delta syndrome, or APDS, who weigh at least 27 kilograms. APDS disrupts immune function.
The new 40 mg and 50 mg tablet strengths expand dosing options for Joenja, or leniolisib. The pediatric regimen also includes 70 mg twice daily for children weighing at least 45 kilograms. Pharming Group N.V. (NASDAQ:PHAR) expects the new strengths in October through its existing distribution and patient-support network.
The expansion arrives as the revenue mix shifts. Second-quarter Joenja revenue increased 40% year over year to $17.9 million, while RUCONEST revenue declined 10% to $72.3 million. Total revenue fell 3% to $90.2 million. Joenja's growth is substantial, but the larger franchise still determines much of the overall result.
Pharming Group N.V. (NASDAQ:PHAR) can bring the pediatric doses to market through an established commercial platform. Distribution relationships and patient support are already in place, which could allow additional sales without duplicating the infrastructure required for an entirely new product.
The opportunity is to spread those capabilities across more eligible patients while maintaining support for existing users. Incremental revenue could improve commercial efficiency, although pediatric servicing costs will still matter.

#revenue #NASDAQ #joenja #pediatric

When planning for retirement, most people account for housing, travel, daily living expenses and general healthcare costs. However, it's easy to overlook one retirement expense: the Income-Related Monthly Adjustment Amount, commonly known as IRMAA.
If you have a large pension, substantial tax-deferred retirement accounts, or other variables that may elevate your retirement income, IRMAA is a factor you may encounter starting in your mid-60s. While it is unlikely to derail a well-constructed financial plan, failing to understand IRMAA and how to plan ahead for it can lead to frustrating annual surprises.
In the United States, most adults become eligible for Medicare when they turn 65. Medicare is divided into several parts, but IRMAA specifically applies to two of them: Part B (which covers doctor visits, outpatient care and preventive services) and Part D (prescription drug coverage).
For the average retiree, Medicare Part B carries a standard monthly base premium ($202.90 per month in 2026). Part D coverage varies depending on the specific private plan selected, but carries a national average base premium of roughly $38.99 per month. Combined, a standard retiree pays roughly $242 per month for basic Part B and Part D coverage, per Medicare.
However, Medicare premiums are not one-size-fits-all. If your income exceeds specific threshold limits set by the federal government, you will be required to pay an additional surcharge on top of your base monthly premiums. That additional surcharge is IRMAA.

#income #base

Parnassus Investments, an investment management company, released the "Parnassus Growth Equity Fund" second-quarter 2026 investor letter. The letter can be downloaded here. During the quarter, the Fund (Investor Shares) returned 17.49% (net of fees), outperforming the Russell 1000 Growth Index's 16.74%. Holdings in Information Technology and Consumer Discretionary sectors boosted relative returns, while Communication Services and Financials holdings detracted. For the year-to-date period, the Fund returned 6.17% (net of fees), outperforming the Russell 1000 Growth's 5.33%. The firm remains constructively bullish on U.S. equities and continues to be selective, valuation-sensitive, and focused on disruptive growth opportunities through active stock selection. Growth stocks advanced during the second quarter, as the Russell 1000 Growth Index generated strong double-digit returns driven by increased confidence in the durability of the ongoing artificial intelligence (AI) infrastructure build-out. Additionally, reviewing the Fund's top five holdings could help identify its best picks for 2026.
In its second-quarter 2026 investor letter, Parnassus Growth Equity Fund highlighted Insmed Incorporated (NASDAQ:INSM). The Fund exited its position in Insmed Incorporated (NASDAQ:INSM), a clinical-stage biotechnology company that develops and commercializes therapies for patients with serious and rare diseases, during the quarter. On September 15, 2026, Insmed Incorporated (NASDAQ:INSM) closed at $119.92 per share. Over the past month, Insmed Incorporated (NASDAQ:INSM) declined 7.49%, but its shares are down 16.51% over the past year. Insmed Incorporated (NASDAQ:INSM) has a market capitalization of $26.19 billion, and its stock has traded within a 52-week range of $90.39 and $212.75.
Parnassus Growth Equity Fund stated the following regarding Insmed Incorporated (NASDAQ:INSM) in its Q2 2026 investor letter:
"Insmed Incorporated (NASDAQ:INSM)shares fell after sales of the biopharmaceutical company's new lung drug Brinsupri fell short of ****** ysts' expectations. We exited the position during the quarter. Insmed's thesis had largely played out following positive TPIP data and upward revisions to Brinsupri sales. We redeployed capital to Twist Bioscience, which offers a longer runway for growth."
Insmed Incorporated (NASDAQ:INSM) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. According to our database, 88 hedge fund portfolios held Insmed Incorporated (NASDAQ:INSM) at the end of the second quarter, compared to 67 in the previous quarter. While we acknowledge the potential of Insmed Incorporated (NASDAQ:INSM) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

#Growth #parnassus

Merck (MRK) was at the center of a major cancer-treatment update in August. Specifically, the drugmaker and Moderna (MRNA) said their personalized mRNA cancer therapy, intismeran autogene, delivered positive results in a Phase 3 study involving 1,137 patients with high-risk melanoma.
Used with Keytruda, the treatment reduced the risk of cancer returning or causing death and improved distant metastasis-free survival compared with Keytruda alone. Merck shares jumped 11% on the news. That was a big move for the stock, which had posted only five single-day gains of more than 5% over the past year.
This High-Yield Construction Stock Just Raised Its Dividend by 40%
Dear Intuit Stock Fans, Mark Your Calendars for September 17
This Dividend Stock Is Staging a Turnaround in 2026 and Pays More Than 2.4%

#Dividend #high #treatment #risk

STERIS plc (STE), with a market capitalization of approximately $20.8 billion, is a global healthcare company focused on infection prevention and patient care. The Mentor, Ohio-based company provides consumable products, capital equipment, maintenance and repair services, sterilization solutions, laboratory testing, outsourced reprocessing, and operating room connectivity solutions.
Companies worth between $10 billion and $200 billion are generally classified as "large-cap stocks," and STERIS fits this description, with its market capitalization reflecting its substantial size and established position within the healthcare sector. STERIS stands out by combining a leading position in infection prevention with a broad range of healthcare and sterilization products and services. Its trusted brand, loyal customer base, strong financial position, and strategic acquisitions strengthen its competitive position while supporting continued expansion and innovation.
Billionaire Charlie Munger, Who Died at 99, Skipped Insurance on His Mansion Since He Could Just Write a Check to Rebuild — 'All Intelligent People Do It My Way'
Nvidia CEO Jensen Huang Just Dropped Huge News for This Cybersecurity Stock
How to Play GME Stock as GameStop CEO Ryan Cohen Buys $20.3 Million in Shares

#steris #position

Auxier ******* et Management, an investment advisory firm, released its second-quarter 2026 investor letter. The letter can be downloaded here. Following a strong rebound from the first-quarter decline, the S&P 500 gained 15.2% as accelerating capital spending toward artificial intelligence infrastructure drove significant gains across technology hardware companies. Semiconductor and data-center-related businesses benefited from supply constraints and strong demand, while enterprise software remained under pressure as investors reassessed AI disruption risks and compressed valuations. In the quarter, Auxier Focus Fund's Investor Class gained 8.82% and 10.70% for the six months ended June 30, 2026. Despite strong earnings growth across the broader market, Auxier highlighted concerns around rising margin debt, increased leverage, and elevated capital flows into high-growth technology areas that could amplify future volatility. The firm continues to focus on identifying enduring businesses with strong competitive advantages, resilient cash flows, and sustainable long-term growth potential. Also, check the fund's top five holdings to see its best picks in 2026.
In its second-quarter 2026 investor letter, Auxier ******* et Management highlighted UnitedHealth Group Incorporated (NYSE:UNH) as a material contributor. UnitedHealth Group Incorporated (NYSE:UNH) is a multinational health benefits company based in Eden Prairie, Minnesota. On September 14, 2026, UnitedHealth Group Incorporated (NYSE:UNH) closed at $383.55 per share. Over the past month, UnitedHealth Group Incorporated (NYSE:UNH) declined 4.38%, while its shares gained 10.86% over the past 52 weeks. UnitedHealth Group Incorporated (NYSE:UNH) has a market capitalization of $344.27 billion with a 52-week trading range between $255.97 and $461.62.
Auxier ******* et Management stated the following regarding UnitedHealth Group Incorporated (NYSE:UNH) in its Q2 2026 investor letter:
"UnitedHealth Group Incorporated (NYSE:UNH) Leads the Way in Reshaping the Insurance Industry with AI UnitedHealth Group is among the companies that have successfully integrated AI into various parts of their operations. One of the most significant benefits has been in administrative functions, where AI has helped save tens of thousands of hours through increased automation and efficiency. As an example, automated transcription of patient encounters has contributed to lower levels of clinician burnout. Management reports that they are generating about $2 of value for every $1 spent on AI due to reductions in manual labor. We like this measured approach to implementing AI where it can provide clear operational benefits and attractive returns, which has been a key strategy of current CEO Stephen Hemsley. UnitedHealth's success in AI use highlights the technology's potential on the user side where companies can benefit without the high upfront cost of building the infrastructure. Cigna Group is projecting $200 million in

BioNTech SE (NASDAQ:BNTX) reported that its investigational lung-cancer drug gotistobart produced a clinically meaningful overall-survival benefit in the Phase 3 PRESERVE-003 trial in patients with metastatic squamous non-small cell lung cancer whose disease had progressed after prior immunotherapy and chemotherapy. Reuters said gotistobart nearly doubled survival compared with standard-of-care chemotherapy, strengthening the case for the drug as a potential chemotherapy-free treatment in a population with significant unmet need.
The result builds on earlier Stage 1 data, where gotistobart reduced the risk of death by 54% versus docetaxel, with a hazard ratio of 0.46. Median overall survival was not yet reached for gotistobart versus 9.95 months for docetaxel, while the 12-month progression-free survival rate was 25.2% versus 0%. BioNTech is now awaiting the pivotal Stage 2 readout, making the latest result important not only for the drug's approval prospects but also for the credibility of BioNTech's broader transition from a COVID-vaccine company toward a multi-product oncology business.
The strongest bullish argument is that gotistobart now has repeated evidence of a meaningful survival advantage in a difficult-to-treat lung-cancer population. The earlier Stage 1 dataset showed 55.6% of patients alive in the gotistobart arm versus 23.8% with docetaxel, alongside a 54% reduction in the risk of death. The latest Phase 3 update reinforces that signal rather than introducing an entirely new hypothesis. If the pivotal Stage 2 data confirm the benefit, BioNTech SE (NASDAQ:BNTX) could have a differentiated therapy capable of competing on survival rather than simply response rates, potentially supporting meaningful pricing power and a commercially attractive oncology franchise.
The result also strengthens BioNTech's broader oncology strategy because gotistobart is one piece of a much larger pipeline rather than a standalone bet. BioNTech says it has 14 ongoing pivotal trials and more than 10 novel combination programs, while its lung-cancer strategy spans more than 16 ongoing clinical trials and five Phase 3 programs. Gotistobart's success therefore provides validation for the company's immuno-oncology capabilities, while other ****** ets such as pumitamig and antibody-drug conjugates advance toward additional indications. BioNTech has identified 17+ late-stage or pivotal readouts through 2030+, creating the possibility that a successful gotistobart launch becomes the first major commercial proof point in its planned transition to a multi-product oncology company.

#stage #survival